Post-Marketing Safety Data for Brexanolone (Zulresso)
In this postmarketing surveillance data analysis, excessive sedation and loss of consciousness when receiving brexanolone occurred at lower rates than previously reported in clinical trials.
Recruiting for Research Study: Pregnenolone Neurosteroid for Menopausal Depression
As of October 2023, the Neurosteroid Intervention for Menopausal and Perimenopausal Depression is no longer recruiting participants. Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. [...]
New Research Study at the CWMH: A Novel Treatment for Menopausal Depression
The transition to menopause, or perimenopause, represents the passage from reproductive to non-reproductive life. During the perimenopause, women experience irregular menstrual cycles, which reflect the large fluctuations in ovarian hormone [...]
Essential Reads: A Comprehensive Review of Brexanolone for the Treatment of Postpartum Depression
This review discusses the novel neurosteroid antidepressant brexanolone for the treatment of postpartum depression.
Essential Reads: Investigational Treatment of Depressive Disorders With Neuroactive Steroids: Potential Implications for PMDD
Neuroactive steroids, derivatives of allopregnanolone, may be effective for the treatment of premenstrual dysphoric disorder.
New Research Study: Pregnenolone Neurosteroid for the Treatment of Menopausal Depression
Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. This class of compounds are steroid hormones produced in the brain and endocrine tissues which can [...]
Development of Zuranolone (SAGE 217) for PPD Will Move Forward
Zuranolone or SAGE-217 is similar to brexanolone (marketed as Zulresso), the medication which was FDA-approved for the treatment of postpartum depression. Zuranolone is a neurosteroid, an analogue of allopregnanolone, which is a positive allosteric [...]
Allopregnanolone Sparks Interest as New PMDD Treatment
Sepranolone is a neuroseroid now in Phase II clinical trials for the treatment of premenstrual dysphoric disorder (PMDD).
Don’t Forget About Brexanolone’s Little Sister: Zuranolone
While we have been talking about using brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant - SAGE 217 or zuranolone - has [...]
Zulresso: Hope and Lingering Questions
Publish date: September 10, 2019 By Lee S. Cohen, MD The last decade has brought increasing awareness of the need to effectively screen for postpartum depression, with a majority of states across the country now having [...]